PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-63.52%
Both yoy net incomes decline, with VET at -3.81%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
30.00%
Some D&A expansion while VET is negative at -2.18%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
128.44%
Some yoy growth while VET is negative at -118.54%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-129.41%
Negative yoy SBC while VET is 337.51%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
4540.00%
Slight usage while VET is negative at -39.33%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
694.58%
AR growth of 694.58% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
-862.36%
Negative yoy inventory while VET is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-232.88%
Negative yoy AP while VET is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
4540.00%
Some yoy usage while VET is negative at -39.33%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
92.42%
Well above VET's 43.20%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
22.06%
Some CFO growth while VET is negative at -21.52%. John Neff would note a short-term liquidity lead over the competitor.
-70.39%
Negative yoy CapEx while VET is 8.56%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
26.38%
Less M&A spending yoy vs. VET's 1433.53%, reducing near-term risk. David Dodd would confirm the firm is not missing out on a strategic deal that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-414.29%
Both yoy lines negative, with VET at -105.61%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-46.02%
We reduce yoy invests while VET stands at 35.32%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-7000.00%
We cut debt repayment yoy while VET is 51.29%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
-27.13%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.